B Cell Lymphoma
From the Journals
CLL combo treatment: Phase-3 study inconclusive
Results of the clinical trial of a CLL drug triplet therapy, presented at ASCO 2023, showed that more data are needed to determine its long-term...
From the Journals
ESMO helps hematologists assess new cancer drugs
The group’s new study evaluation tool, the ESMO-MCBS:H, is aimed at helping doctors and others determine the benefit of new blood cancer therapies...
Article
NORD: Making Progress Through Collaboration
Conference Coverage
Multiprong strategy makes clinical trials less White
Only a small percentage of eligible patients participate in clinical trials in the first place, and very few come from racial and ethnic minority...
Conference Coverage
Huge underuse of germline testing for cancer patients
Information from germline genetic testing could affect a patient’s cancer care.
Conference Coverage
DEI training gives oncology fellows more confidence
Only 2%-3% of practicing oncologists are Black or Hispanic/Latino, says Yale Cancer Center doctor.
Feature
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant south of Ahmedabad, India, and found hundreds of trash bags...
Conference Coverage
CLL: Venetoclax-obinutuzumab combo effective long term
Progression-free survival benefit of 1 year with venetoclax-obinutuzumab is sustained long term in chronic lymphocytic leukemia, trial analysis...
News
FDA approves glofitamab for DLBCL
Glofitamab, a T cell–engaging bispecific antibody, has been approved by the Food and Drug Administration for adults with DLBCL.
Conference Coverage
CAR-T hikes overall survival in relapsed/refractory LBCL
Investigators say axi-cel should become the standard of care for second-line large B-cell lymphoma.
Feature
Widespread carboplatin, cisplatin shortages: NCCN survey
Only 64% of centers said they are still able to continue treating all current patients receiving carboplatin.